Trv Gp Vi LLC Takes Position in Rapport Therapeutics (NASDAQ:RAPP)

TRV GP VI LLC purchased a new position in shares of Rapport Therapeutics (NASDAQ:RAPP - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 969,218 shares of the company's stock, valued at approximately $17,194,000. Rapport Therapeutics makes up approximately 14.7% of TRV GP VI LLC's holdings, making the stock its 3rd biggest holding. TRV GP VI LLC owned approximately 2.65% of Rapport Therapeutics at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Geode Capital Management LLC purchased a new position in shares of Rapport Therapeutics in the 3rd quarter worth approximately $4,133,000. Jennison Associates LLC purchased a new position in shares of Rapport Therapeutics during the 4th quarter valued at about $1,105,000. State Street Corp purchased a new stake in shares of Rapport Therapeutics in the third quarter worth about $1,189,000. Norges Bank acquired a new stake in Rapport Therapeutics during the fourth quarter worth about $860,000. Finally, Swiss National Bank acquired a new stake in Rapport Therapeutics during the fourth quarter worth about $319,000.

Insiders Place Their Bets

In related news, Director Wendy B. Young purchased 6,000 shares of Rapport Therapeutics stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average price of $10.21 per share, for a total transaction of $61,260.00. Following the transaction, the director now directly owns 6,000 shares in the company, valued at approximately $61,260. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Troy A. Ignelzi acquired 9,900 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was purchased at an average price of $10.10 per share, for a total transaction of $99,990.00. Following the completion of the acquisition, the chief financial officer now owns 9,900 shares in the company, valued at $99,990. The trade was a ∞ increase in their position. The disclosure for this purchase can be found here.

Wall Street Analyst Weigh In

RAPP has been the topic of several recent research reports. Citizens Jmp initiated coverage on Rapport Therapeutics in a research report on Tuesday, April 8th. They issued a "mkt outperform" rating on the stock. JMP Securities began coverage on shares of Rapport Therapeutics in a research note on Tuesday, April 8th. They issued a "market outperform" rating and a $28.00 target price for the company. Four investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $32.67.

Rapport Therapeutics Stock Down 4.8 %

Shares of RAPP stock traded down $0.53 during trading hours on Friday, hitting $10.57. 35,534 shares of the company's stock were exchanged, compared to its average volume of 177,074. Rapport Therapeutics has a fifty-two week low of $6.43 and a fifty-two week high of $29.74. The firm has a market cap of $385.76 million and a P/E ratio of -0.77. The firm has a 50 day moving average of $10.11 and a two-hundred day moving average of $16.52.

Rapport Therapeutics Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.